NASDAQ:AAPG Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis $37.38 +1.50 (+4.18%) As of 06/20/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Ascentage Pharma Group International Stock (NASDAQ:AAPG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AAPG alerts:Sign Up Key Stats Today's Range$36.40▼$37.9550-Day Range$18.72▼$37.3852-Week Range$16.50▼$37.95Volume25,208 shsAverage Volume12,757 shsMarket Capitalization$3.26 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Read More… Receive AAPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address AAPG Stock News HeadlinesEHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALLJune 15, 2025 | globenewswire.comThirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual CongressJune 9, 2025 | globenewswire.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.June 21, 2025 | Timothy Sykes (Ad)Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral ReportJune 2, 2025 | globenewswire.comLive from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid TumorsJune 2, 2025 | globenewswire.comAscentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025May 22, 2025 | globenewswire.comIs Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?May 12, 2025 | msn.comAscentage Pharma Group International ADRApril 30, 2025 | morningstar.comSee More Headlines AAPG Stock Analysis - Frequently Asked Questions How have AAPG shares performed this year? Ascentage Pharma Group International's stock was trading at $18.67 at the beginning of 2025. Since then, AAPG stock has increased by 100.2% and is now trading at $37.38. View the best growth stocks for 2025 here. When did Ascentage Pharma Group International IPO? Ascentage Pharma Group International (AAPG) raised $126 million in an initial public offering on Friday, January 24th 2025. The company issued 7,325,000 shares at $17.25 per share. When does Ascentage Pharma Group International's lock-up period expire? Ascentage Pharma Group International's lock-up period expires on Wednesday, July 23rd. Ascentage Pharma Group International had issued 7,325,000 shares in its initial public offering on January 24th. The total size of the offering was $126,356,250 based on an initial share price of $17.25. After the end of Ascentage Pharma Group International's lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Who are Ascentage Pharma Group International's major shareholders? Top institutional investors of Ascentage Pharma Group International include Monashee Investment Management LLC (0.18%). How do I buy shares of Ascentage Pharma Group International? Shares of AAPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AAPG Previous SymbolNASDAQ:AAPG CIK2023311 WebN/A Phone86 512 8555 7777FaxN/AEmployees600Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio3.24 Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$134.35 million Price / Sales24.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book77.88Miscellaneous Outstanding Shares87,120,000Free FloatN/AMarket Cap$3.26 billion OptionableN/A BetaN/A 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:AAPG) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.